Inventor · disambiguated record

Lena Wullkopf

Also filed as: WULLKOPF LENA

2 granted patents·24 pending applications·0 citations·filing 2021–2024

51Inventor score

Technology areasA61K

Files withIMMATICS BIOTECHNOLOGIES GMBH26

Top patents by PatentIndex Score

26 records

0190US2024239865A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
0290US2024166713A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
0390US2024166717A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
0490US2024239866A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
0590US2024166715A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
0690US2024247045A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
0790US2024166716A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
0890US2024239867A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
0990US2024166714A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1090US2024254191A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1190US2024166712A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1289US2024158460A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1389US2024117004A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
1489US2024067697A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
1589US2024132570A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1689US2024218044A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1789US2024158461A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1889US2024109949A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
1989US2024247044A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
2089US2024279306A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
2189US2024150430A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
2289US2024150429A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
2389US2024117003A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
2489US2024141013A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
2587US11952409B2Amidated peptides and their deamidated counterparts displayed by non-HLA-A*02 for use in immunotherapy against different types of cancers preliminary classIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Granted Apr 9, 2024·0 cites·20 claims
2681US11891427B2Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 6, 2024·0 cites·20 claims

Join the waitlist — get patent alerts

Get an alert when Lena Wullkopf files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →